RedHill Biopharma Extends Option Agreement for Phase II-Stage Pancreatic Cancer Drug RP101
July 15, 2015 07:00 ET
|
RedHill Biopharma Ltd.
RedHill has extended the term of the exclusive option agreement for the oncology drug candidate RP101 for an additional year
RP101 is a proprietary, first-in-class, orally-administered,...